Gepants: an encouraging alternative to triptans

Real world experience with gepants is supporting the clinical trial data, the ANZHS 2021 ASM was told. Professor Andrew Charles, director of the UCLA Goldberg Migraine Program in the US, told the meeting they had treated about 1,000 patients – largely as acute therapy given only recent approval of rimegepant as preventive therapy. He said ...

Already a member?

Login to keep reading.

© 2021 the limbic